IMR Press / FBL / Volume 21 / Issue 6 / DOI: 10.2741/4449

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Radionuclide imaging and treatment of thyroid cancer

Show Less
1 Department of Nuclear Medicine, Shan Xi Tumor Hospital, Shan Xi, 030013, China
2 Department of Nuclear Medicine, The First Hospital of Shan Xi Medical University, Shan Xi, 030012, China
Front. Biosci. (Landmark Ed) 2016, 21(6), 1187–1193;
Published: 1 June 2016
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)

Over the past decades, the diagnostic methods and therapeutic tools for thyroid cancer (TC) have been greatly improved. In addition to the classical method of ingestion of radioactive iodine-131 (I131) and subsequent I123 and I124 positron emission tomography (PET) in therapy and examination, I124 PET-based 3-dimensional imaging, Ga68-labeled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-NaI(3)-octreotide (DOTANOC) PET/computed tomography (CT), Tc99m tetrofosmin, pre-targeted radioimmunotherapy, and peptide receptor radionuclide therapy have all been used clinically. These novel methods are useful in diagnosis and therapy of TC, but also have unavoidable adverse effects. In this review, we will discuss the development of nuclear medicine in TC examination and treatment.

Thyroid Cancer
Radionuclide Imaging
Back to top